NCT01996709

Brief Summary

The purpose of this study is to assess improvement of palpebral roughness and associated symptoms with 3 months use of Clear Care®.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
142

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2013

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2013

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 27, 2013

Completed
4 days until next milestone

Study Start

First participant enrolled

December 1, 2013

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2014

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

June 8, 2015

Completed
Last Updated

June 8, 2015

Status Verified

May 1, 2015

Enrollment Period

5 months

First QC Date

November 18, 2013

Results QC Date

May 26, 2015

Last Update Submit

May 26, 2015

Conditions

Keywords

Silicone hydrogel contact lensesMulti-purpose solutionLid PapillaePalpebral Roughness

Outcome Measures

Primary Outcomes (1)

  • Mean Change From Baseline in Investigator Rated Lid Papillae Maximum Score at Day 90

    Lid papillae (bumps on the inner eyelid) were assessed by the investigator using slit-lamp biomicroscopy and classified independently for the four palpebral zones (upper lid=1-3; lower lid=4) on a 5-point forced choice scale, where 0 = None; 1 = Slight (diffuse papillae); 2 = Mild (diffuse \& tufts papillae); 3 = Moderate (moderate \& tufts papillae); 4 = Severe (giant papillae). The maximum of the four zones was selected for the analysis. Both eyes were included in the model for analysis. A higher change value indicates a larger reduction in the severity of the lid papillae.

    Baseline (Day 0), Day 90

Secondary Outcomes (3)

  • Top 2 Box Percentage Agreement for "My Lenses Feel Like New" at Day 90

    Day 90

  • Mean Frequency Score for Symptoms of Grittiness at Day 90

    Day 90

  • Mean Frequency Score for Symptoms of Dryness at Day 90

    Day 90

Study Arms (2)

Clear Care

EXPERIMENTAL

Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days

Device: Hydrogen peroxide-based contact lens solutionDevice: Habitual contact lenses

Habitual MPS

ACTIVE COMPARATOR

Habitual contact lens solution used with habitual contact lenses for 90 days

Device: Habitual contact lens solutionDevice: Habitual contact lenses

Interventions

Also known as: Clear Care®
Clear Care

Biguanide-preserved

Habitual MPS

Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule

Clear CareHabitual MPS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Current biweekly or monthly silicone hydrogel contact lens wearer (excluding Air Optix® brand) and have worn these lenses bilaterally for at least three (3) months prior to Visit 1 (daily wear use only).
  • Symptoms of contact lens discomfort as defined by the protocol.
  • Habitual use of a biguanide-preserved multi-purpose solution for at least 30 days prior to Visit 1.
  • Mild to severe (grade 2-4) Investigator rated palpebral roughness in one or more zones of either eye.

You may not qualify if:

  • Extended (over-night) contact lens wearer.
  • Any systemic or ocular disease or disorder (refractive disorder allowed and mild dry eye with successful contact lens wear is permitted), complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study.
  • Topical ocular over the counter (OTC) or prescribed medications, with the exception of contact lens rewetting drops, within 7 days of enrollment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Refractive Errors

Condition Hierarchy (Ancestors)

Eye Diseases

Results Point of Contact

Title
Jessie Lemp, DrPH, GMA Brand Lead
Organization
Alcon Research, Ltd.

Study Officials

  • Lisa Zoota, MPH

    Alcon Research

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2013

First Posted

November 27, 2013

Study Start

December 1, 2013

Primary Completion

May 1, 2014

Study Completion

May 1, 2014

Last Updated

June 8, 2015

Results First Posted

June 8, 2015

Record last verified: 2015-05